Qlife Holding – Introduction to market segment and demonstration of Egoo
Meet Qlife Holding’s CEO Thomas Warthoe who will tell us more about one of their segments; dieticians & nutritionist, who are dealing with patients with systemic low-grade inflammation, what it is, and what solution the company offer to this.
This event will explain one of the main drivers for Qlife and Egoo Health.
Inflammation is defined by increased CRP levels. Low-grade inflammation is defined with CRP levels 3-10 mg/L. Low-grade inflammation can be caused by an unhealthy lifestyle that includes smoking, a poor diet, alcohol consumption, stress, and weight gain.
A CRP quantitative test was launched on the Egoo System earlier this year to allow monitoring of inflammation levels and to target this growing lifestyle market.
The event takes place on the 15th of June at 10.00 am CEST. After the presentation, you are more than welcome to ask questions.
Qlife Holding strives to revolutionize the market for clinical biomarkers. The company has developed Egoo Health which is a nextgen self-testing at-home biomarker platform. It is designed to simplify testing procedures for at-home test scenarios. The C-Reactive Protein (CRP) test is launched and can be ordered on www.egoo.health/egoo-shop. Other clinical lifestyle biomarker tests such as HbA1c, Lipids, Vitamin D, hormones, and more will be launched continuously.
The company is on a quest to empower people with more accessible ways to understand their health - so that they can move beyond reactive care towards proactive wellbeing. It's how Qlife wants to contribute to improving quality of life for every individual and for the greater society.
Disclaimer: HC Andersen Capital receives payment from Qlife Holding for a DigitalIR/Corporate Visibility agreement./ Claus Thestrup 6 June 2023 at 2:PM.
